Erasca (ERAS)
(Real Time Quote from BATS)
$2.56 USD
+0.02 (0.59%)
Updated Aug 6, 2024 03:55 PM ET
After-Market: $2.54 -0.02 (-0.78%) 4:18 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
Erasca, Inc. [ERAS]
Reports for Purchase
Showing records 1 - 6 ( 6 total )
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
RAS Focus Expands with In-Licensing and Reprioritization: Reit. Buy and Lowering Our PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
Multiple MAPK Catalysts May Provide Significant Upside in 2024; Reit Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
Naporafenib Leads MAPK Assault with Data in 2/4Q24; Reit. Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Progress and Prioritization Refine MAPK Assault Strategy; Reit Buy and Lowering Our PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
Rich Catalyst Calendar Looks to Showcase an Assault on MAPK; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Erasca, Inc.
Industry: Medical - Biomedical and Genetics
An Oncogenic MAPK Assault on All Fronts; Initiating with a Buy Rating and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
|